National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 32371-32372 [2017-14641]

Download as PDF Federal Register / Vol. 82, No. 133 / Thursday, July 13, 2017 / Notices Catholic Health Initiatives Patient Safety Organization, LLC of its status as a PSO, and has delisted the PSO accordingly. DATES: The directories for both listed and delisted PSOs are ongoing and reviewed weekly by AHRQ. The delisting was effective at 12:00 Midnight ET (2400) on June 15, 2017. ADDRESSES: Both directories can be accessed electronically at the following HHS Web site: https:// www.pso.ahrq.gov/listed. FOR FURTHER INFORMATION CONTACT: Eileen Hogan, Center for Quality Improvement and Patient Safety, AHRQ, 5600 Fishers Lane, Room 06N94B, Rockville, MD 20857; Telephone (toll free): (866) 403–3697; Telephone (local): (301) 427–1111; TTY (toll free): (866) 438–7231; TTY (local): (301) 427–1130; Email: pso@ahrq.hhs.gov. SUPPLEMENTARY INFORMATION: sradovich on DSK3GMQ082PROD with NOTICES Background The Patient Safety and Quality Improvement Act of 2005, 42 U.S.C. 299b–21 to b–26, (Patient Safety Act) and the related Patient Safety and Quality Improvement Final Rule, 42 CFR part 3 (Patient Safety Rule), published in the Federal Register on November 21, 2008, 73 FR 70732– 70814, establish a framework by which hospitals, doctors, and other health care providers may voluntarily report information to Patient Safety Organizations (PSOs), on a privileged and confidential basis, for the aggregation and analysis of patient safety events. The Patient Safety Act authorizes the listing of PSOs, which are entities or component organizations whose mission and primary activity are to conduct activities to improve patient safety and the quality of health care delivery. HHS issued the Patient Safety Rule to implement the Patient Safety Act. AHRQ administers the provisions of the Patient Safety Act and Patient Safety Rule relating to the listing and operation of PSOs. The Patient Safety Rule authorizes AHRQ to list as a PSO an entity that attests that it meets the statutory and regulatory requirements for listing. A PSO can be ‘‘delisted’’ if it is found to no longer meet the requirements of the Patient Safety Act and Patient Safety Rule, when a PSO chooses to voluntarily relinquish its status as a PSO for any reason, or when a PSO’s listing expires. Section 3.108(d) of the Patient Safety Rule requires AHRQ to provide public notice when it removes an organization from the list of federally approved PSOs. VerDate Sep<11>2014 17:41 Jul 12, 2017 Jkt 241001 AHRQ has accepted a notification from the Catholic Health Initiatives Patient Safety Organization, LLC, a component entity of the Catholic Health Initiatives, PSO number P0162, to voluntarily relinquish its status as a PSO. Accordingly, the Catholic Health Initiatives Patient Safety Organization, LLC was delisted effective at 12:00 Midnight ET (2400) on June 15, 2017. The Catholic Health Initiatives Patient Safety Organization, LLC has patient safety work product (PSWP) in its possession. The PSO will meet the requirements of section 3.108(c)(2)(i) of the Patient Safety Rule regarding notification to providers that have reported to the PSO and of section 3.108(c)(2)(ii) regarding disposition of PSWP consistent with section 3.108(b)(3). According to section 3.108(b)(3) of the Patient Safety Rule, the PSO has 90 days from the effective date of delisting and revocation to complete the disposition of PSWP that is currently in the PSO’s possession. More information on PSOs can be obtained through AHRQ’s PSO Web site at https://www.pso.ahrq.gov. Sharon B. Arnold, Deputy Director. [FR Doc. 2017–14702 Filed 7–12–17; 8:45 am] BILLING CODE 4160–90–P DEPARTMENT OF HEALTH AND HUMAN SERVICES 32371 The Committee provides advice and recommendations on policy and program development to the Secretary of the Department of Health and Human Services (Secretary) concerning the medicine and dentistry activities under section 747 of the Public Health Services (PHS) Act, as it existed upon the enactment of Section 749 of the PHS Act in 1998. The Committee is responsible for preparing and submitting an annual report to the Secretary and Congress describing the activities of the Committee, including findings and recommendations made by the Committee. Amendment of the ACTPCMD charter clarifies the authorization and duties of the Committee regarding medicine and dentistry as it operates and conducts its business. A copy of the ACTPCMD charter is available on the ACTPCMD Web site at https://www.hrsa.gov/ advisorycommittees/bhpradvisory/ actpcmd/. A copy of the charter is also available on the Federal Advisory Committee Act (FACA) database that is maintained by the Committee Management Secretariat under the General Services Administration. The Web site for the FACA database is https:// www.facadatabase.gov/. SUPPLEMENTARY INFORMATION: Jason E. Bennett, Director, Division of the Executive Secretariat. [FR Doc. 2017–14648 Filed 7–12–17; 8:45 am] Health Resources and Services Administration BILLING CODE 4165–15–P Advisory Committee on Training in Primary Care Medicine and Dentistry DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Service Administration (HRSA), Department of Health and Human Services. ACTION: Notice of charter amendment. AGENCY: The Department of Health and Human Services is hereby giving notice that the Advisory Committee on Training in Primary Care Medicine and Dentistry (ACTPCMD) has been amended. The effective date of the renewed charter is May 31, 2017. FOR FURTHER INFORMATION CONTACT: Kennita R. Carter, M.D., Designated Federal Official, Division of Medicine and Dentistry, Bureau of Health Workforce, HRSA, in one of three ways: (1) Send a request to the following address: Kennita R. Carter, M.D., Designated Federal Official, Division of Medicine and Dentistry, HRSA, 5600 Fishers Lane, 15N–116, Rockville, Maryland 20857; (2) call 301–945–3505; or (3) send an email to KCarter@ hrsa.gov. SUMMARY: PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special E:\FR\FM\13JYN1.SGM 13JYN1 32372 Federal Register / Vol. 82, No. 133 / Thursday, July 13, 2017 / Notices Emphasis Panel; NIAID Clinical Trial Implementation Cooperative Agreement (U01). Date: August 2, 2017. Time: 10:00 a.m. to 12:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call). Contact Person: Audrey O. Lau, MPH, Ph.D., Scientific Review Officer, Scientific Review Program, DEA/NIAID/NIH/DHHS, 5601 Fishers Lane, MSC–9823, Rockville, MD 20852, 240–669–2081. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: July 7, 2017. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–14641 Filed 7–12–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting sradovich on DSK3GMQ082PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Neurosurgeon Research Career Development Program (NRCDP) Review. Date: July 25, 2017. Time: 2:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Elizabeth A. Webber, Ph.D., Scientific Review Officer, Scientific Review Branch, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3204, MSC 9529, Bethesda, MD 20892– 9529, (301) 496–1917, webbere@mail.nih.gov. VerDate Sep<11>2014 17:41 Jul 12, 2017 Jkt 241001 (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS) Dated: July 7, 2017. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–14642 Filed 7–12–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Office of the Secretary Amended; Notice of Meeting Notice is hereby given of a change in the meeting of the Task Force on Research Specific to Pregnant Women and Lactating Women scheduled for August 21–22, 2017, in Conference Room 6, C-Wing, 31, which was published in the Federal Register on April 18, 2017, 82 FR 18305. The agenda for the meetings are listed below: August 21, 2017—Day 1 8:30 a.m. Welcome and Opening Remarks 8:40 a.m. Introductions 9:15 a.m. Background, Timeline, Goals and Reports 9:45 a.m. Scope of the Task Force 11:15 a.m. Identification of Federal Activities 5:00 p.m. End of Day 1 August 22, 2017—Day 2 8:30 a.m. Recap of Day 1, Outline and Goals of Day 2 8:45 a.m. Panel Discussion: Recommendations for coordination of and collaboration on research related to pregnant women and lactating women 10:45 a.m. Open Public Presentations 12:30 p.m. Panel Presentations and Discussion: Dissemination of research findings and information relevant to pregnant women and lactating women to providers and the public 3:00 p.m. Outline Overarching Recommendations from Panels 4:15 p.m. Recap of Meeting, Action Items, Charge to Group 4:30 p.m. End of Day 2, Adjourn Meeting In addition to filing written comments, oral comments from the public will be scheduled for approximately 10:45 a.m.–11:30 a.m. on August 22, 2017. Any member of the PO 00000 Frm 00057 Fmt 4703 Sfmt 4703 public interested in presenting oral comments to the committee on August 22, 2017, must notify the Contact Person by 5:00 p.m. on Monday, August 7, 2017. Interested individuals and representatives of organizations must submit a letter of intent, a brief description of the organization represented, and a short description of the oral presentation. Only one representative of an organization may be allowed to present oral comments and if accepted by the committee, presentations may be limited to three to five minutes per speaker depending on the number of speakers to be accommodated within the allotted time. Speakers will be assigned a time to speak in the order of the date and time when their request to speak is received. Both printed and electronic copies are requested for the record. Any changes to the meeting agenda, including tentative times, as well as other relevant additional information about the meeting will be posted on the Web site for the Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC) located at: https://www.nichd.nih.gov/about/ advisory/PRGLAC/Pages/index.aspx. Dated: July 7, 2017. Anna Snouffer, Deputy Director, Office of Federal Advisory Committee Policy. [FR Doc. 2017–14643 Filed 7–12–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY Coast Guard [Docket No. USCG–2017–0544] Merchant Mariner Medical Advisory Committee Coast Guard, Department of Homeland Security. ACTION: Notice of Federal Advisory Committee teleconference meeting. AGENCY: The Merchant Mariner Medical Advisory Committee working group will meet via teleconference to work on Task Statement 25, review of the draft Merchant Mariner Medical Manual, to complete the discussions from its April 4–5, and May 8, 2017 meetings. The teleconference will be open to the public. DATES: The Merchant Marine Mariner Medical Advisory Committee working group is scheduled to meet via teleconference on Thursday, August 17, 2017, from 2 p.m. until 5 p.m. Eastern Standard Time. Please note that this SUMMARY: E:\FR\FM\13JYN1.SGM 13JYN1

Agencies

[Federal Register Volume 82, Number 133 (Thursday, July 13, 2017)]
[Notices]
[Pages 32371-32372]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-14641]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special

[[Page 32372]]

Emphasis Panel; NIAID Clinical Trial Implementation Cooperative 
Agreement (U01).
    Date: August 2, 2017.
    Time: 10:00 a.m. to 12:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 5601 Fishers Lane, 
Rockville, MD 20892 (Telephone Conference Call).
    Contact Person: Audrey O. Lau, MPH, Ph.D., Scientific Review 
Officer, Scientific Review Program, DEA/NIAID/NIH/DHHS, 5601 Fishers 
Lane, MSC-9823, Rockville, MD 20852, 240-669-2081.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: July 7, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-14641 Filed 7-12-17; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.